Hirano Kojiro, Hirano Yuni, Yu Miharu, Tei Yuka, Shimane Toshikazu
Department of Otorhinolaryngology - Head and Neck Surgery, Showa Medical University, Tokyo, JPN.
Department of Dermatology, Showa Medical University, Tokyo, JPN.
Cureus. 2025 May 26;17(5):e84827. doi: 10.7759/cureus.84827. eCollection 2025 May.
Atopic dermatitis (AD) often presents challenges in treating external ear lesions and frequently exhibits resistance to conventional therapies. This case report describes a 49-year-old male patient with a history of AD and habitual ear cleaning who developed chronic external otitis that was refractory to topical steroids and steroid ear drops. The patient demonstrated significant improvement following the administration of a topical Janus kinase (JAK) inhibitor, delgocitinib ointment. Delgocitinib effectively suppressed interleukin-31 (IL-31), thereby interrupting the itch-scratch cycle and facilitating the resolution of inflammation. This case suggests that delgocitinib ointment is a promising therapeutic alternative for refractory external ear eczema in patients with AD. Further studies are warranted to evaluate its long-term efficacy and safety in otological applications.
特应性皮炎（AD）在治疗耳部外病变时常常面临挑战，并且对传统疗法常常表现出耐药性。本病例报告描述了一名49岁男性患者，有特应性皮炎病史且有习惯性耳部清洁行为，他患上了慢性外耳道炎，对局部用类固醇和类固醇耳滴剂治疗无效。在使用局部Janus激酶（JAK）抑制剂——地尔戈替尼软膏后，患者病情有显著改善。地尔戈替尼有效抑制白细胞介素-31（IL-31），从而中断瘙痒-搔抓循环并促进炎症消退。本病例表明，地尔戈替尼软膏对于患有特应性皮炎的难治性外耳道湿疹患者是一种有前景的治疗选择。有必要进一步开展研究以评估其在耳科应用中的长期疗效和安全性。
